1007488-73-4

Usage

Uses

Used in Pharmaceutical Industry:
[1-(propan-2-yl)-1H-pyrazol-5-yl]methanol is used as a reagent for the synthesis of heterocyclic compounds, which are essential in the development of new pharmaceuticals. Its role in creating these compounds aids in the advancement of drug discovery and the treatment of various medical conditions.
Used in Agrochemical Industry:
In the agrochemical industry, [1-(propan-2-yl)-1H-pyrazol-5-yl]methanol is used as an intermediate for the production of various agrochemical compounds. Its application in this field contributes to the development of new products that can enhance crop protection and improve agricultural practices.
Used in Organic Synthesis:
[1-(propan-2-yl)-1H-pyrazol-5-yl]methanol is also utilized in organic synthesis as a building block for creating a wide range of chemical compounds. Its versatility in this area allows for the development of new materials and substances with potential applications in various industries.
It is crucial to handle [1-(propan-2-yl)-1H-pyrazol-5-yl]methanol with care and adhere to all safety guidelines and regulations when using it in a laboratory or industrial setting to ensure the safety of both the users and the environment.

Upstream product

• 100305-93-9 1-isopropyl-1H-pyrazole-5-carbaldehyde 
• 18952-87-9 1-isopropyl-1H-pyrazole 

Relevant academic research and scientific papers

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

Myeloid cell leukemia 1 (Mcl-1) has emerged as an attractive target for cancer therapy. It is an antiapoptotic member of the Bcl-2 family of proteins, whose upregulation in human cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy. Here we report the discovery of our clinical candidate S64315, a selective small molecule inhibitor of Mcl-1. Starting from a fragment derived lead compound, we have conducted structure guided optimization that has led to a significant (3 log) improvement of target affinity as well as cellular potency. The presence of hindered rotation along a biaryl axis has conferred high selectivity to the compounds against other members of the Bcl-2 family. During optimization, we have also established predictive PD markers of Mcl-1 inhibition and achieved both efficient in vitro cell killing and tumor regression in Mcl-1 dependent cancer models. The preclinical candidate has drug-like properties that have enabled its development and entry into clinical trials.

NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.